Skip to main content
IMS Events Main banner

    Pieter Sonneveld, MD, PhD (he/him/his)

    President
    EMN
    Rotterdam, Netherlands

    Pieter Sonneveld, MD, Ph.D. was born in The Netherlands. He received his medical degree from the Erasmus University in Rotterdam, The Netherlands in 1977. In 1980 he completed a Ph.D. thesis on the pharmacology of Adria­mycin in Acute Leukemia at the University of Leiden (DW van Bekkum & HM Pinedo, pro­ motores). He received a Fogarty Fellowship and worked for several years at the National Cancer Institute, Bethesda, USA.

    He is chairman of the HOVON Myeloma Wor­king Group and he coordinates HOVON and EMN clinical trials for multiple myeloma. Dr. Sonneveld helped to found the European Mye­ loma Network EMN and has been its chairman since 2005. Within EMN, he coordinates a cooperative network for independent clinical trials in Europe and initiates efforts to create international standards for diagnostics and patient care. EMN currently runs 12 interna­ tional trials, several of which are independent registration trials for novel treatments.
    He has been Board member (2011-) and Presi­ dent (2017-2019) of the European Hematology Association EHA, and occupies the chair of its Scientific Working Group Committee. He has chaired the Scientific Program Committee of the 19th EHA congress in Milan 2014 and of the EMN Myeloma meetings in 2018 and 2020.

    He serves on the Scientific Advisory Boards of the IMF and MMRF and is a board member of the International Myeloma Society and has been a member of the Editorial Boards of Blood, Leukemia, Eur J Cancer and Haematologica. Dr. Sonneveld has authored more than 600 peer reviewed scientific publi­ cations and several book chapters.

    In 2015 he was awarded the prestigious inter­ national Robert Kyle life time achievements Award in MM. In 2019 he recei­ved the Hubertus Wald Award for Cancer Research from Germany, in 2022 the International Waldenström Liefetime Achievement Award and in 2025 the Otto Kahler Award.

    Disclosure information not submitted.

    Presentation(s):